文献速递姑息放疗与转移瘤放疗物理与技术

18F-NaF PET/CT评估前列腺癌骨转移单次SABR疗效

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy.
PubMed 文献 · Radiat Oncol · 2019-09-05

本研究在前列腺癌骨转移患者中,于单次立体定向消融放疗(SABR)前后行18F-NaF PET/CT,评估肿瘤SUVmax变化及非肿瘤骨摄取与剂量的关系。结果显示33个病灶中29个SUVmax下降,非肿瘤骨受照剂量越高摄取丢失越明显,并观察到边缘复发。

要点

  • 单次SABR后6个月,33个骨转移灶中29个SUVmax下降。
  • 非肿瘤骨摄取丢失随SABR剂量增加而增大,24 Gy处中位丢失23.3%。
  • 出现边缘复发提示骨转移治疗或需更大临床靶体积。

核心结论

  • 18F-NaF PET/CT评估单次SABR后骨转移显示肿瘤及高剂量非肿瘤骨成骨活性明显降低。
  • 边缘复发的出现提示骨转移治疗可能需要更大的临床靶体积。

研究设计与样本

  • 前瞻性试验中接受单次SABR的骨转移患者,SABR前后行18F-NaF PET/CT扫描。
  • 测定肿瘤SUVmax及非肿瘤骨摄取随SABR剂量的变化。

主要发现

  • 33个病灶中29个在SABR后6个月SUVmax下降,平均绝对下降17.7(95%CI 25.8至-9.4,p=0.0001)。
  • 3个SUVmax升高的病灶中,2个来自同一患者位于脊柱,判定为局部进展并1处骨折。
  • 第3个SUVmax升高病灶位于肋骨,局部控制但24个月时发生骨折。
  • 2例患者观察到治疗体积邻近进展。
  • 非肿瘤骨受照剂量越高摄取丢失越明显,接受24 Gy的骨中位摄取丢失23.3%。

临床怎么用

  • 18F-NaF PET/CT可用于单次SABR后骨转移成骨活性的疗效评估。
  • 对脊柱等部位治疗后SUVmax升高需警惕局部进展或骨折。
  • 边缘复发提示制定骨转移SABR靶区时需考虑扩大临床靶体积。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In prostate cancer patients, imaging of bone metastases is enhanced through the use of sodium fluoride positron emission tomography (18F-NaF PET/CT). This imaging technique shows areas of enhanced osteoblastic activity and blood flow. In this work, 18F-NaF PET/CT was investigated for response assessment to single fraction stereotactic ablative body radiotherapy (SABR) to bone metastases in prostate cancer patients. METHODS: Patients with bone metastases in a prospective trial treated with single fraction SABR received a 18F-NaF PET/CT scan prior to and 6 months post-SABR. The SUVmax in the tumour was determined and the difference between before and after SABR determined. The change in uptake in the non-tumour bone was also measured as a function of the received SABR dose. RESULTS: Reduction in SUVmax was observed in 29 of 33 lesions 6 months after SABR (mean absolute decrease in SUVmax 17.7, 95% CI 25.8 to - 9.4, p = 0.0001). Of the three lesions with increased SUVmax post-SABR, two were from the same patient and located in the vertebral column. Both were determined to be local progression in addition to one fracture. The third lesion (in a rib) was shown to be controlled locally but suffered from a fracture at 24 months. Progression adjacent to the treated volume was observed in two patients. The non-tumour bone irradiated showed increased loss in uptake with increasing dose, with a median loss in uptake of 23.3% for bone receiving 24 Gy. CONCLUSION: 18F-NaF PET/CT for response assessment of bone metastases to single fraction SABR indicates high rates of reduction of osteoblastic activity in the tumour and non-tumour bone receiving high doses. The occurrence of marginal recurrence indicates use of larger clinical target volumes may be warranted in treatment of bone metastases. TRIAL REGISTRATION: POPSTAR, 'Pilot Study of patients with Oligometastases from Prostate cancer treated with STereotactic Ablative Radiotherapy', Universal Trial Number U1111-1140-7563 , Registered 17th April 2013.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hardcastle N, Hofman MS, Lee CY, et al. NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. Radiat Oncol. 2019. PMID: 31488175. doi:10.1186/s13014-019-1359-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。